Article (Scientific journals)
New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen, André; Ernest, Philippe
2002In Diabetes and Metabolism, 28 (6 Pt 1), p. 437-45
Peer Reviewed verified by ORBi
 

Files


Full Text
New antiobesity agents in type 2 diabetes.pdf
Author postprint (71.84 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anti-Obesity Agents/therapeutic use; Appetite Depressants/therapeutic use; Blood Glucose/metabolism; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Cyclobutanes/therapeutic use; Diabetes Mellitus/drug therapy; Diabetes Mellitus, Type 2/drug therapy; Humans; Lactones/therapeutic use; Obesity; Weight Loss
Abstract :
[en] Besides genetic predisposition, obesity is the most important risk factor for the development of type 2 diabetes mellitus. Even modest weight reduction can improve blood glucose control in overweight subjects. After failure of lifestyle modifications, antiobesity drugs such as orlistat, a potent and selective inhibitor of gastric and pancreatic lipases that reduces lipid intestinal absorption, or sibutramine, a noradrenaline and 5-hydroxytryptamine reuptake inhibitor that regulates food intake, may be considered to favour weight loss and/or weight maintenance. Several placebo-controlled studies have recently demonstrated that both drugs are able to promote weight loss in obese type 2 diabetic patients treated with diet alone, sulphonylureas, metformin or insulin. The greater weight reduction as compared to placebo was associated with a significant reduction of glycated haemoglobin levels and/or of the doses of classical antihyperglycaemic agents, especially in good responders who lost at least 10% of initial body weight. In addition, vascular risk factors associated to insulin resistance were also reduced after weight loss. These antiobesity agents may also contribute to delay or prevent the progression from impaired glucose tolerance to overt type 2 diabetes in at risk obese individuals ("Xenical in the prevention of diabetes in obese subjects" trial). Large long-term prospective studies, such as the "Sibutramine cardiovascular and diabetes outcome study" should better determine the place of pharmacological anti-obesity strategy in the overall management of obese patients with impaired glucose tolerance or type 2 diabetes.
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Ernest, Philippe ;  Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Publication date :
2002
Journal title :
Diabetes and Metabolism
ISSN :
1262-3636
eISSN :
1878-1780
Publisher :
Masson, Moulineaux Cedex 9, France
Volume :
28
Issue :
6 Pt 1
Pages :
437-45
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 26 May 2009

Statistics


Number of views
432 (7 by ULiège)
Number of downloads
740 (3 by ULiège)

Scopus citations®
 
52
Scopus citations®
without self-citations
34
OpenAlex citations
 
50

Bibliography


Similar publications



Contact ORBi